While high expression is consistently associated with worse survival outcomes, the absence or low expression of Cyclin D1 appears to have variable effects, potentially influenced by differences in tumor biology, molecular subtypes, and methodological approaches across studies. The gene discussed is CCND1; the disease is neoplasm.